ER positive HER2 negative breast cancer

June 2, 2023

Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial

By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for patients

Dr. Shipra Gandhi & Dr. Arya Mariam Roy - Updates From ASCO23: X-7/7 Trial

Breast Cancer/News/Opinion

Updates from ASCO2023 – The SONIA Trial

By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors with endocrine therapy are the current standard of care for first-line treatment in advanced estrogen receptor-positive (ER+) HER2-negative breast cancer.

June 5, 2023

Breast Cancer/News/Opinion

Updates from ASCO2023 – The SONIA Trial

By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors with endocrine therapy are the current standard of care for first-line treatment